Abstract
Mammalian sirtuins (SIRT1-7) are NAD+-dependent deacetylases, which play an important role in aging and in a wide range of cellular functions. SIRT1, the best-characterized member of the family, acts as a sensor of the redox state and triggers in the cell the appropriate defense response. A large body of evidence has showed that SIRT1 induces both cellular and systemic protective effects in the cardiovascular system by preventing stress-induced apoptosis and senescence, and mitigating endothelial dysfunction. Hence, SIRT1 is now foreseen as a potential therapeutic target for a growing number of cardiovascular diseases. Recently, it has been suggested that SIRT1 activation could also be considered as a neuroprotective strategy. Indeed, SIRT1 protects against ischemia/reperfusion injury both in vitro and in vivo and avoids severe ischemic damage by preserving cerebral blood flow. In the last years it was suggested that others sirtuins, in particular SIRT3 and SIRT6, could exert beneficial effects in vascular syndromes. The aim of this review was to describe and discuss recent experimental evidence on the effects of SIRT1 and other sirtuins on the pathophysiology of cardio- and cerebrovascular diseases, underlying a potential therapeutic effect of these enzymes in the treatment and/or prevention of such conditions.
Keywords: SIRT1, SIRT3, SIRT6, drugs, vascular function.
Current Drug Targets
Title:Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases
Volume: 18 Issue: 4
Author(s): Valeria Conti, Maurizio Forte, Graziamaria Corbi, Giusy Russomanno, Luigi Formisano, Alessandro Landolfi, Viviana Izzo, Amelia Filippelli, Carmine Vecchione and Albino Carrizzo
Affiliation:
Keywords: SIRT1, SIRT3, SIRT6, drugs, vascular function.
Abstract: Mammalian sirtuins (SIRT1-7) are NAD+-dependent deacetylases, which play an important role in aging and in a wide range of cellular functions. SIRT1, the best-characterized member of the family, acts as a sensor of the redox state and triggers in the cell the appropriate defense response. A large body of evidence has showed that SIRT1 induces both cellular and systemic protective effects in the cardiovascular system by preventing stress-induced apoptosis and senescence, and mitigating endothelial dysfunction. Hence, SIRT1 is now foreseen as a potential therapeutic target for a growing number of cardiovascular diseases. Recently, it has been suggested that SIRT1 activation could also be considered as a neuroprotective strategy. Indeed, SIRT1 protects against ischemia/reperfusion injury both in vitro and in vivo and avoids severe ischemic damage by preserving cerebral blood flow. In the last years it was suggested that others sirtuins, in particular SIRT3 and SIRT6, could exert beneficial effects in vascular syndromes. The aim of this review was to describe and discuss recent experimental evidence on the effects of SIRT1 and other sirtuins on the pathophysiology of cardio- and cerebrovascular diseases, underlying a potential therapeutic effect of these enzymes in the treatment and/or prevention of such conditions.
Export Options
About this article
Cite this article as:
Conti Valeria, Forte Maurizio, Corbi Graziamaria, Russomanno Giusy, Formisano Luigi, Landolfi Alessandro, Izzo Viviana, Filippelli Amelia, Vecchione Carmine and Carrizzo Albino, Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases, Current Drug Targets 2017; 18 (4) . https://dx.doi.org/10.2174/1389450116666151019095903
DOI https://dx.doi.org/10.2174/1389450116666151019095903 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ECMO for Refractory Hypoxia; Current State of the Art and Future Directions
Current Respiratory Medicine Reviews Cardiovascular Magnetic Resonance Imaging: State of the Art
Current Cardiology Reviews Meet Our Editorial Board Member:
Central Nervous System Agents in Medicinal Chemistry Targeting Transient Receptor Potential Canonical Channels for Diseases of the Nervous System
Current Drug Targets Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Toll-Like Receptor 4 Signaling Pathway as a Potential Targets for Stroke-Induced Inflammation
Current Signal Transduction Therapy Penehyclidine Hydrochloride Protects Rat Cardiomyocytes from Ischemia- Reperfusion Injury by Platelet-derived Growth Factor-B
Combinatorial Chemistry & High Throughput Screening 5-HT1A Receptor, an Old Target for New Therapeutic Agents
Current Topics in Medicinal Chemistry Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets The Effect of Acori Graminei Rhizoma and Extract Fractions on Spatial Memory and Hippocampal Neurogenesis in Amyloid Beta 1-42 Injected Mice
CNS & Neurological Disorders - Drug Targets Inhibition of IκB Phosphorylation by a Novel IKK Inhibitor IMD-1041 Attenuates Myocardial Dysfunction After Infarction
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Characterization of Adipose-Derived Stem Cells: An Update
Current Stem Cell Research & Therapy Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Isoflavones, Equol and Cardiovascular Disease: Pharmacological and Therapeutic Insights
Current Medicinal Chemistry Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets <i>Hoslundia opposita</i> Vahl. - A Promising Source of Bioactive Compounds against Infectious and Non-infectious Diseases
Current Traditional Medicine LIMD2 is the Signature of Cell Aging-immune/Inflammation in Acute Myocardial Infarction
Current Medicinal Chemistry A Simple and Rapid Method for Expression and Purification of Functional TNF-α Using GST Fusion System
Current Pharmaceutical Biotechnology The Design of Competitive, Small-molecule Inhibitors of Coagulation Factor Xa
Current Topics in Medicinal Chemistry